Damora Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(90,948) | $(9,103) |
| Adjustment to reconcile net loss to net cash used in operating activities: | ||
| Depreciation of equipment | 16 | 16 |
| Share-based compensation | 16,819 | 515 |
| Gain on sale of IP | (750) | — |
| Amortization of premium and discount on marketable securities, net | (293) | — |
| Issuance of ordinary shares in connection with vesting of restricted share units | — | 38 |
| Amortization of right-of-use lease asset | 327 | 11 |
| Accretion of lease liability | — | 5 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (40) | 482 |
| Other assets, noncurrent | (461) | (671) |
| Accounts payable | 5,639 | 143 |
| Accrued expenses and other current liabilities | 10,447 | 1,281 |
| Operating lease liability | (59) | (15) |
| Paramora warrant obligation | 11,862 | — |
| Related party accounts payable and other current liabilities | (12,258) | — |
| Other liabilities, noncurrent | — | 6 |
| Net cash used in operating activities | (59,699) | (7,292) |
| Cash flows from investing activities | ||
| Purchase of marketable securities | (179,503) | — |
| Proceeds from sale of IP | 750 | — |
| Net cash used in investing activities | (178,753) | — |
| Cash flows from financing activities | ||
| Issuance of ordinary shares in connection with offerings | 351,509 | — |
| Issuance costs in connection with offerings | (21,667) | — |
| Proceeds from exercise of options | 703 | — |
| Net cash provided by financing activities | 330,545 | — |
| Net increase (decrease) in cash and cash equivalents | 92,093 | (7,292) |
| Effect of exchange rate changes on cash and cash equivalents | (61) | 723 |
| Cash and cash equivalents, beginning of period | 257,624 | 14,175 |
| Cash and cash equivalents, end of period | $349,656 | $7,606 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for taxes | $5 | $5 |
| Supplemental disclosures of noncash activities: | ||
| Operating lease liability arising from obtaining right-of-use assets | $1,089 | $— |
| Unrealized loss on marketable securities | $(974) | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.